强生关闭心血管和代谢药物部门_老虎社区_美港股上老虎

强生关闭心血管和代谢药物部门

药渡09-28

据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。本次重组主要影响心血管部门的商业工作，而非研发。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。心血管和代谢部门的核心产品是拜瑞妥（利伐沙班），这是强生与拜耳合作开发的抗凝药，曾是世界上最畅销的药物之一...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2470613700?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-28 07:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2470613700","market":"us","top_or_hot":-1,"title":"强生关闭心血管和代谢药物部门","media":"药渡","content":"<div>\n<p>据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。本次重组主要影响心血管部门的商业工作，而非研发。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。心血管和代谢部门的核心产品是拜瑞妥（利伐沙班），这是强生与拜耳合作开发的抗凝药，曾是世界上最畅销的药物之一...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409280743039582b5fe&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生关闭心血管和代谢药物部门</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生关闭心血管和代谢药物部门\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-28 07:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409280743039582b5fe&s=b><strong>药渡</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。本次重组主要影响心血管部门的商业工作，而非研发。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。心血管和代谢部门的核心产品是拜瑞妥（利伐沙班），这是强生与拜耳合作开发的抗凝药，曾是世界上最畅销的药物之一...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409280743039582b5fe&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409280743039582b5fe&s=b","article_id":"2470613700","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409280743039582b5fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2470613700","pubTimestamp":1727479847,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。强生的医疗器械部门在心血管领域的业务未受影响，仍在积极进行相关收购和研发活动：·今年8月份，强生将以6亿美元的预付款收购V-Wave。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4534":"瑞士信贷持仓","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","BK4581":"高盛持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4504":"桥水持仓","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","BK4592":"伊斯兰概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4532":"文艺复兴科技持仓","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","JNJ":"强生","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC"},"translate_title":"Johnson & Johnson closes cardiovascular and metabolic drugs unit","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。本次重组主要影响心血管部门的商业工作，而非研发。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。心血管和代谢部门的核心产品是拜瑞妥（利伐沙班），这是强生与拜耳合作开发的抗凝药，曾是世界上最畅销的药物之一。但由于美国政府的医疗保险价格谈判，拜瑞妥的价格降低了62%。强生的医疗器械部门在心血管领域的业务未受影响，仍在积极进行相关收购和研发活动：·今年8月份，强生将以6亿美元的预付款收购V-Wave。·今年4月，强生份以131亿美元现金收购Shockwave所有流通股，该公司专注于开发钙化心血管疾病治疗的产品，并全球首推产品“冲击波球囊导管”。·2022年，强生公司以166亿美元收购了医疗设备制造商Abiomed。该公司的王牌产品为Impella心脏泵。2023年9月，强生宣布品牌焕新，将旗下医疗科技和制药两大业务整合至强生（Johnson & Johnson）名下。其中，制药业务杨森更名为强生创新制药（Johnson & Johnson Innovative Medicine）。这家制药公司一直淡化其心血管和代谢业务，将研发重点缩小到三个治疗领域：肿瘤学、免疫学和神经科学。强生在2024年进行了多项收购和研发活动，包括收购Proteologix获得免疫学双抗资产、收购Numab获得IL-4R/IL-31双抗、收购Ambrx开发下一代ADC产品等。公司发言人表示，这是强生在复杂和快速变化的外部环境中适应和发展业务的必要举措。来源：药研网、思齐俱乐部","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}